Compare Cenovus Energy Inc (CVE) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cenovus Energy Inc vs Neurocrine Biosciences Inc — how do they compare? Cenovus Energy Inc trades at $29.93 (market cap $54.43B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Cenovus Energy Inc is far larger — about 3.2× Neurocrine Biosciences Inc's market cap, and Cenovus Energy Inc pays a 2.11% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| CVE | NBIX | |
|---|---|---|
Market Cap | $54.43B | $16.76B |
Sector | Energy | Health |
52-Week High | $31.80 | $185.50 |
52-Week Low | $14.83 | $123.10 |
Enterprise Value | $60.50B | $16.78B |
Dividend Yield | 2.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cenovus Energy (CVE) trades at $28.25, showing neutral momentum with strong fundamental metrics including a P/E of 10.99 and ROE of 20.96%. Recent Q2 2026 earnings matched expectations at $1.11 EPS, while revenue and production growth remain robust. Technical indicators show mixed signals with RSI neutral and moving averages bullish, trading near key support at $28.
The outlook remains positive with projected 2026 revenue growth to $58B and net income of $6.7B, supported by strong cash flow generation. Risks include oil price volatility and refining pressures, but analyst consensus leans bullish with 40.7% buy ratings. The stock presents value opportunity given attractive valuation multiples and dividend yield.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
